Open AccessCould iPSCs Enable “Off-the-Shelf” Cell Therapy?
Author(s) -
Diana Crow
Publication year - 2019
Publication title -
cell
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 26.304
H-Index - 776
eISSN - 1097-4172
pISSN - 0092-8674
DOI - 10.1016/j.cell.2019.05.043
Subject(s) - induced pluripotent stem cell , off the shelf , biology , cell therapy , clinical trial , bioinformatics , stem cell , microbiology and biotechnology , embryonic stem cell , computer science , genetics , gene , software engineering
An "off-the-shelf" cell therapy derived from induced pluripotent stem cells (iPSCs) has entered clinical trials in the United States. Other companies are following suit, harnessing iPSCs' self-renewal ability to manufacture cell therapies that don't require customization for each patient. But some experts aren't sure such therapies are a good idea.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom